Czy możemy stosować tocilizumab u chorych na reumatoidalne zapalenie stawów z wysokim ryzykiem sercowo-naczyniowym? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2019
Słowa kluczowe:
tocilizumab, powikłania sercowo-naczyniowe, reumatoidalne zapalenie stawów, leki biologiczne
##plugins.themes.bootstrap3.article.main##
Abstrakt
Większa aktywność reumatoidalnego zapalenia stawów zwiększa ryzyko wystąpienia chorób sercowo-naczyniowych, co ma związek z oddziaływaniem na stężenie cytokin prozapalnych i markerów zapalnych, które mogą również promować miażdżycę tętnic. Tocilizumab jest skuteczny w terapii reumatoidalnego zapalenia stawów, a zaburzenia lipidowe obserwowane w trakcie leczenia nim nie zwiększają średniego wskaźnika aterogenności ani ryzyka wystąpienia epizodów sercowo-naczyniowych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kur-Zalewska, J., & Dąbrowski , R. (2019). Czy możemy stosować tocilizumab u chorych na reumatoidalne zapalenie stawów z wysokim ryzykiem sercowo-naczyniowym?. Medycyna Faktów , 12(2(43), 115-119. https://doi.org/10.24292/01.MF.0219.5
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Goodson N., Marks J., Lunt M., Symmons D.: Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann. Rheum. Dis. 2005; 64: 1595-1601.
2. Lindhardsen J., Ahlehoff O., Gislason G.H. et al.: The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann. Rheum. Dis. 2011; 70: 929-934.
3. Van Helm V.P., Nielen M.M., Nurmohamed M.T. et al.: Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66: 184-188.
4. Khovidhunkit W., Kim M.S., Memon R.A. et al.: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid. Res. 2004; 45: 1169-1196.
5. Choy E., Sattar N.: Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann. Rheum. Dis. 2009; 68: 460-469.
6. Kaplan M.J.: Cardiovascular disease in rheumatoid arthritis. Curr. Opin. Rheumatol. 2006; 18: 289-297.
7. Agca R., Heslinga S.C., Rollefstad S. et al.: EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann. Rheum. Dis. 2017; 76: 17-28.
8. Bacchiega B.C., Bacchiega A.B., Usnayo M.J. et al.: Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study. J. Am. Heart Assoc. 2017; 6: e005038.
9. Charakterystyka produktu leczniczego: RoActemra.
10. Smolen J.S., Landewé R., Bijlsma J. et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 2017; 0: 1-18. DOI: 10.1136/annrheumdis-2016-210715.
11. Maini R.N., Taylor P.C., Szechinski J. et al.: Double-Blind Randomized Controlled Clinical Trial of the Interleukin-6 Receptor Antagonist, Tocilizumab, in European Patients With Rheumatoid Arthritis Who Had an Incomplete Response to Methotrexate. Arthritis Rheum. 2006; 54: 2817-2829.
12. Giles J.T., Sattar N., Gabriel S.E. et al.: Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel-group, multicenter, noninferiority, phase 4 clinical trial. Arthr. Rheumatol. 2016; 68(10): 4357-4359.
13. Nishimoto N., Miyasaka N., Yamamoto K. et al.: Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann. Rheum. Dis. 2009; 68: 1580-1584. DOI: 10.1136/ard.2008.092866.
14. Jones G., Wallace T., McIntosh M.J. et al.: Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study. J. Rheumatol. 2017; 44: 2. DOI: 10.3899/jrheum.160287.
15. Rao V.U., Pavlov A., Klearman M. et al.: An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy. Arthritis Rheumatol. 2015; 67: 372-380.
16. Schiff M.H., Kremer J.M., Jahreis A. et al.: Integrated safety in tocilizumab clinical trials. Arthritis Res. Ther. 2011; 13(5): R141. DOI: 10.1186/ar3455.
17. Yamamoto K., Goto H., Hirao K. et al.: Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan. J. Rheumatol. 2015; 42: 8.
18. Kim S.C., Solomon D.H., Rogers J.R. et al.: Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis. A Multi-Database Cohort Study. Arthritis Rheum. 2017; 69(6): 1154-1164.
2. Lindhardsen J., Ahlehoff O., Gislason G.H. et al.: The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann. Rheum. Dis. 2011; 70: 929-934.
3. Van Helm V.P., Nielen M.M., Nurmohamed M.T. et al.: Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66: 184-188.
4. Khovidhunkit W., Kim M.S., Memon R.A. et al.: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid. Res. 2004; 45: 1169-1196.
5. Choy E., Sattar N.: Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann. Rheum. Dis. 2009; 68: 460-469.
6. Kaplan M.J.: Cardiovascular disease in rheumatoid arthritis. Curr. Opin. Rheumatol. 2006; 18: 289-297.
7. Agca R., Heslinga S.C., Rollefstad S. et al.: EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann. Rheum. Dis. 2017; 76: 17-28.
8. Bacchiega B.C., Bacchiega A.B., Usnayo M.J. et al.: Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study. J. Am. Heart Assoc. 2017; 6: e005038.
9. Charakterystyka produktu leczniczego: RoActemra.
10. Smolen J.S., Landewé R., Bijlsma J. et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 2017; 0: 1-18. DOI: 10.1136/annrheumdis-2016-210715.
11. Maini R.N., Taylor P.C., Szechinski J. et al.: Double-Blind Randomized Controlled Clinical Trial of the Interleukin-6 Receptor Antagonist, Tocilizumab, in European Patients With Rheumatoid Arthritis Who Had an Incomplete Response to Methotrexate. Arthritis Rheum. 2006; 54: 2817-2829.
12. Giles J.T., Sattar N., Gabriel S.E. et al.: Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel-group, multicenter, noninferiority, phase 4 clinical trial. Arthr. Rheumatol. 2016; 68(10): 4357-4359.
13. Nishimoto N., Miyasaka N., Yamamoto K. et al.: Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann. Rheum. Dis. 2009; 68: 1580-1584. DOI: 10.1136/ard.2008.092866.
14. Jones G., Wallace T., McIntosh M.J. et al.: Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study. J. Rheumatol. 2017; 44: 2. DOI: 10.3899/jrheum.160287.
15. Rao V.U., Pavlov A., Klearman M. et al.: An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy. Arthritis Rheumatol. 2015; 67: 372-380.
16. Schiff M.H., Kremer J.M., Jahreis A. et al.: Integrated safety in tocilizumab clinical trials. Arthritis Res. Ther. 2011; 13(5): R141. DOI: 10.1186/ar3455.
17. Yamamoto K., Goto H., Hirao K. et al.: Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan. J. Rheumatol. 2015; 42: 8.
18. Kim S.C., Solomon D.H., Rogers J.R. et al.: Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis. A Multi-Database Cohort Study. Arthritis Rheum. 2017; 69(6): 1154-1164.